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Controversies in regional anaesthesia – patient
on anticoagulant therapy
INTRODUCTION
There are many advantages of spinal or epidural analgesia/anest-hesia over general anesthesia in patients undergoing orthopedic
surgery including reduced postoperative cardiovascular and pulmo-
nary complications, blood loss, need for transfusion and decreased
incidence of thromboembolic complications. Many studies confirmed
reduction in perioperativemortality andmorbidity including reduction
in incidence of thromboembolic complications if operative procedures
are performed under regional anesthesia. A meta analysis of randomiz-
ed trials revealed that the use of perioperative regional anesthesia can
decrease mortality by approximately 30 %, deep venous thrombosis by
44 %, pulmonary embolism by 55 %, respiratory depression by 59 % and
the need for transfusion by 55 % (1).
The rationale for thromboprophylaxis is based on the high preva-
lence of venous thromboembolism among hospitalised patients. The
highest incidence of thromboembolic complications is among ortho-
paedic patients scheduled for total joint replacement surgery. Without
thromboprophylaxis the prevalence of deep venous thrombosis is over
50% after total knee or hip replacement surgery. The incidence of calf
deep venous thrombosis (DVT) is 40% to 80%, proximal DVT 10% to
20%, clinical pulmonary embolism (PE) 4% to 10%, fatal PE 0.2% to
5% (2).However, the high incidence of thromboembolic complications
is confirmed after general surgery procedures, after urologic, gyneco-
logic and trauma surgery. In many patients, multiple risk factors are
present, and the risks are cumulative. Formal risk assesment models for
DVT or PE have been proposed for surgical patients. According to risk
assesment models the prophylaxis recommendations are used in peri-
operative treatment. In a random survey of fellows of the American
College of Surgeons, 86 % claimed they used prophylaxis in 1993, this
proportion rising to 96 % by 1997 (3).
There are many recommendations how to perform thrombopro-
phylaxis. The most popular are ACCP (American College of Chest
Phycians) recommendations, but there are also ESA (Europena Society
of Anesthesia) recommendations and national recommendations. For
example, the initial recommendationswere presented in 1986 byACCP
stated that patients undergoing hip or knee arrhoplasty receive dextran,
adjusted dose standard heparin (approximately 3500 U every 8 hours),
warfarin (started 48 hours preoperatively to achieve a prothrombin time
(PT) 1.25 – 1.5 times baseline), or dextran plus intermittent pneumatic
compression. The duration of thromboprophylaxis is continued after
hospital discharge for a total of 10 to 35 days.
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Overview
The ACCP guidelines are widely recognized as a
practice standard for VTEprevention and treatment, and
have been regularly updated throughout recent decades.
The most recent version, issued in 2012, is formally
known as the 9th ACCP Conference on Antithrombotic
and Thrombolytic Therapy (4).
The combination of regional anesthesia and throm-
bopropylaxis is standard for many operative procedures.
Unfortunately serious complications like perispinal he-
matoma can occur after spinal or epidural anesthesia
performed in patients receiving thromboprophylaxis. Epi-
dural hematoma is defined as a rare, but potentially
catastrophic complications of spinal or epidural anesthe-
sia. Although rare, the seriousness of this complication
mandates very cautious use of antithrombotic medica-
tions in patients having neuraxial blockade. In a review
of the literature between 1906 and 1994 year 61 cases of
spinal hematoma associated with epidural or spinal anes-
thesia have been reported (5).
In response to these serious complications the Ame-
rican Society of Regional Anesthesia and Pain Medicine
(ASRA) held three Consensus Conferences on Regional
Anesthesia and Anticoagulation where recommendations
how to perform regional anesthesia in patients receiving
anticoagulation drugs were achieved. ASRA consensus
represents the opinions of experts based on cases reports,
clinical series and risks factors for surgical bleeding (6).
In last two decades new antithrombotic drugs are
introduced for thromboprophylaxis in orthopedic and
others surgical patients and there is question how to
perform regional anesthesia procedures with concom-
mitant use of antithrombotic drugs in order to avoid
serious bleeding complications. At same time the number
of patients receiving antiplatelet drugs is also increased.
Many patients with a coronary stent require surgery
during antiplatelet thrapy, so the question is how to
perform regional anesthesia in these patients or is regio-
nal anesthesia contraindicated.
Perioperative management of patients
who are receiving VKA therapy
Many patients with prosthetic cardiac valves, atrial
fibrillation, hypercoagulable conditions are chronically
treated with oral anticoagulants. Patients with DVT or
PEare treatedwith oral anticoagulants for severalmonths.
Oral anticoagulants are also used for thromboprophyl-
axis following many surgical procedures. Oral anticoagu-
lants interferes with the synthesis of the vitamin K-de-
pendent clotting factors, factor II (thrombin), VII, IX
and X.
In patients undergoing major surgery or procedures
interruption of VKA (Vitamin K antagonists) therapy is
required tominimize perioperative bleeding. The neura-
xial anesthesia is contraindicated during oral anticoagu-
lant therapy that is not interrupted prior to surgery. Is
important to achieve normal or near-normal hemostasis
at the time when procedure of regional anesthesia is per-
formed. The residuals pharmacodynamic effect of VKAs
and the associated time need for the regeneration of vita-
min K-dependent coagulation factors. Elimination half-
-life of VKA is 8 to 11 h for acenocoumarol and 36 to 42 h
for warfarin. Each half-life elapsed corresponds to 50%
reduction in anticoagulant affect. Theoretically, since the
PT and INR reflect dominantly factor VII activity (factor
VII has only a 6-8 h half-life) there might be interval
during during wich PT and INR approach normal levels
but factors II and X levels are not be adequate for hemo-
stasis. Bleeding may occur if the level of any clotting
factor is decreased to 20 – 40% of baseline. Adequate
levels of all vitamin K dependent factors are present
when INR is in the normal range. INR value of 1.5 is
associated with factor VII activity of 40%. Thus, an INR
< 1.5 should be associated with normal hemostasis (7).
Many patients perioperatively should receive bridging
anticoagulationduring interruption ofVKA therapy.Bridg-
ing anticoagulation means the administration of a short
acting anticoagulant during interruption of VKA therapy
when INR is not within a therapeutic range aiming to
minimize the risk for thromboembolism, such as stroke
and systemic embolism in patients with a mechanical
heart valve or atrial fibrillation and to minimize the risk
for recurrent thrombosis in patients with prior VTE. In
high risk patients the therapeutic dose (the dose that is
similar to that used for acute VTE or acute coronary
syndrome) of low molecular weight heparins (LMWH)
or unfractioned heparin (UFH) is proposed. In patients
with moderate risk the prophylactic dose is recommend-
ed (the dose that is used typically to prevent postoperative
VTE) (8).
Regional anesthesia management of the patient receiv-
ing VKA antagonists
1. Discontinue VKA antagonists 5 days preoperatively
and verify PTnormalization before neuraxial block.
2. In patients with a mechanical heart valve, atrial
fibrillation or VTE at high risk for thromboem-
bolism the bridging therapy with LMWH is sug-
gested during interruption of VKA therapy.
3. Mmonitor the PT and INR daily.
4. Neuraxial anestheis or removing indwelling neur-
axial catheters are possible when the INR is < 1.5
Low molecular weight heparins (LMWH)
Great importance of spinal hematomawas recognised
after approval of LMWH for clinical use. LMWH hepa-
rins are in use in Europe from 1989 and in USA from
1993. In 1997, only 4 years after the release of LMWH for
general use in USA in May 1993, a series of 43 patients
who had developed perispinal hematoma after receiving
the LMWH enoxaparin concurrently with spinal or epi-
dural anesthesia have been reported. Many of these pa-
tients suffered neurologic impairment, including per-
manent paralysis, despite decompressive laminectomy.
Themedian age was 78 years (28-90), and 78% of patients
were women. Concomitant antiplatelet therapy was pre-
sent in several cases. Nearly 90% of these complications
occured in patients receiving enoxaparin as prophylaxis
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after primarily total knee or hip replacement. Many of
these events occurred when LMWH was given intraope-
ratively or early postoperatively to patients undergoing
continuous epidural anesthesia and analgesia. At same
time 10 cases of spinal hematoma have been reported in
Europe. The possible explanation for this apparent dif-
ference in incidence in Europe may be a result of a diffe-
rence in dose and dose schedule. For example, in Europe
the recommended dose of enoxaparin is 40mg once daily
initiated 12 hours preoperatively while in USA is 30 mg
twice daily. The predisposing factors also include the
presence of an underlying hemostatic disorder, traumatic
needle or catheter insertion, repeated insertion attempts
or blood return, time of catheter insertion or removal, use
of continuous epidural catheters, administration of me-
dications known to increase bleeding. Manufacturers of
LMWHs subsequently added a boxed warning to the
prescribing information, alerting clinicians to this poten-
tial effect. However, it became clear that at least some of
these outcomes resulted from lack of attention to timing
of the neuraxial anesthesia relative to the dose of LMWH,
traumatic needle placement, and catheter removal dur-
ing therapeutic levels of anticoagulation. Inmany patients
the impact of renal function is underestimated. In patients
with severe renal insufficiency the anticoagulant effect is
exaggerated ant the elimination half live prolonged from
4–5 to as long as 16 hours (9).
Regional anesthesia management
of the patient receiving LMWH
Preoperative LMWH
1. Perform neuraxial techniques at least 10–12 h after
a thromboprophylaxis dose and 24 h after a high
therapeutic dose of LMWH.
Postoperative LMWH – twice dosing regimen
1. With twice daily dosing administer first dose no
earlier than 24 h after operation.
2. Remove indwelling catheters before initiation of
LMWH thromboprophylaxis.
3. The first dose of LMWH administered 2 h after
catheter removal and 24 h after needle/catheter
placement.
Postoperative LMWH – once dosing regimen
1. Once daily dosing requires 6–8 h between needle/
catheter placement ant the first dose of LMWH.
New anticoagulants
Because of great importance of thromboprophylaxis
anticoagulated drugs are under permanent investiga-
tions. All new drugs have focused their developement on
trying to posses the characteristics of the ideal anticoagu-
lant. These characteristics include: possibility of oral (one
tablet, once daily) and parenteral (once daily) adminstra-
tion, high effectivity in reducing thromboembolic events,
low rate of complications (focus on bleeding), possibility
of reversal, predictable pharmacokinetics, predictable dose
response, rapid onset of action, no need for routine mo-
nitoring, wide therapeutic window, no dose adjustment
required, no interaction with other drugs and inhibition
of both free and clot-bound activated coagulation factors.
Of course no licensedmedication has all these properties.
New antithrombotic drugs that target various steps in
the hemostatic system with many of these properties are
continuously under development. The most extensivelly
studied are direct Factor X and thrombin inhibitors.
Many of these agents have prolonged half-lives and are
difficult to reverse without administration of blood com-
ponents. In last decade three new anticoagulation drugs
are licensed for thromboprophylaxis in orthopedic sur-
gery. There are two Factor X selective inhibitors (paren-
terally administered Fondaparinux and perorally admini-
stered Rivaroxaban) andDabigatran, new direct thrombin
inhibitor given perorally. After serious complications re-
ported with introduction of LMWH in clinical use spe-
cial caution is given to regional aneshesia and these drugs.
The administration of these drugs in combination with
regional anesthesia must be carefully considered. Im-
portantly, until large series become available, we can ap-
ply lessons learned from LMWH experience to develop
initial management recommendations.
Fondaparinux
Fondaparinux is licensed for the prevention of venous
thromboembolism (VTE) in high risk patients. It is an
injectable synthetic pentasaccharide that acts indirectly
on factor Xa via antithrombin III. Fondaparinux was
approved in December 2001 and FDA released fond-
aparinux (Arixtra) with a block box warning similar to
that of the LMWHs and heparinoids. It is highly selec-
tive, without any effect on factor IIa (thrombin) or plate-
lets. Its half life is 17 - 20 hours in normal individuals
allowing for single-daily dose, but may be significantly
prolonged in patients with renal impairment. In the
perioperative setting fondaparinux treatment should start
6 hours postoperatively, provided surgical haemostasis is
secured. Kidney function sholud be monitored. Investi-
gators reported a spinal hematoma among the initial
dose-ranging study. No additional spinal hematoma was
reported in the combined series of 3600 patients who
underwent spinal or epidural anesthesisin in combina-
tion with fondaparinux thromboprophylaxis.
Nevertheless, its use in orthopedic patients has re-
mained somewhat limited. This may be because of con-
cerns over possible increased bleeding risk relative to
some other anticoagulants. Because of bleeding risk, fond-
aparinux is contraindicated in patients who weigh less
than 50 kg, and its package insert recommends caution
when it is used in the elderly due to an increased risk of
bleeding in patients aged 65 or older. Additionally, the
Pentasaccharide inMajor Knee Surgery (PENTAMAKS)
study found fondaparinux to be associated with a signi-
ficantly higher incidence of major bleeding compared
with enoxaparin (2.1% vs 0.2%; p=0.006) in major knee
surgery, although it was superior to enoxaparin in pre-
venting VTE. Other possible reasons for slow adoption
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of fondaparinux include its long half-life, which results
in a sustained antithrombotic effect, its lack of easy rever-
sibility, and a contraindication in patients with renal
insufficiency.
Anesthetic management of the patient
receiving Fondaparinux
The actual risk of spinal hematoma with fondaprinux
is unknown. Consensus statement are based on the sus-
tained and irreversible antithrombotic effect, early post-
operative dosing and the spinal hematoma reported dur-
ing initial clinical trials.
1. The first dose is administered no less than 6 hours
after completion of central nerve blockade (CNB).
2. In patients with ongoing treatment, fondaparinux
should be witheld at least 36 hours before the ini-
tiation of a CNB.
Until further clinical experience is available, perfor-
mance od neuraxial technique should occur under condi-
tions used in clinical trials (single-needle pass, atraumatic
needle placement, avoidance of indwelling neuraxial
catheters). If this is not feasible, an alternate method of
prophylaxis should be considered. (11, 12)
Rivaroxaban
Rivaroxaban is a potent selective and reversible oral
activated factorXa inhibitor, with an oral biovaliability of
80%. It is approved for use in Europe and Canada for
tromboprophylaxis after total hip or knee replacement.
There are many clinical trials comparing rivaroxaban
with LMWH (enoxaparin) in patients with joint re-
placement. According these studies rivaroxaban have su-
periority with less incidence or thromboembolic events
and simplicity of oral administration. Current studies are
assessing the role of rivaroxaban in treating thrombosis
and prophylaxis of VTE in medical patients and in pre-
venting arterial thromboembolism in both high-risk atrial
fibrillation and acute coronary syndrome patients.
Rivaroxaban has predictable pharmacokinetics with
high oral biovaliability and a rapid onset of action. The
absorbtion after oral intake is nearly 100%. The peak
level is reached at 2–4 hours, and its half life is 5–9 hours.
Inhibition is maintained for 12 hours. After admini-
stration approximately 66% undergoes metabolic degra-
dation, with half being eliminated renally and the other
half through fecal route. The final 33% undergoes direct
renal excretion mainly through active renal secretion.
Elimination half life is 9 hours in healthy subjects and is
prolonged to 13 hours in elderly with decline in renal
function (dose adjustment is needed in patients with
renal insufficiency). For patients in whom rivaroxaban is
indicated, no coagulation monitoring is required.
In patients with hip or knee arthroplasty the recom-
mended dose is an oral once-daily 10 mg tablet. The first
dose should be given 6–8 hours after wound closure. It is
not necessary to adjust dose in the presence of mild or se-
vere renal impairment (creatine clearance 15–80 ml/min)
and it is contraindicated in hepatic desease with coagu-
lopathy and clinical bleeding risk, and shuld be used
with caution in patients with moderate hepatic impair-
ment.
Anesthetic management of the patient
receiving Rivaroxaban
1. Folowing a CNB, there should be a delay of on less
than 6 hours before rivaroxaban treatment is ini-
tiated (24 hours if the procedure has been trau-
matic or bloody).
2. In patients with ongoing treatment, there should
be a delay of no less than 18 hours between the last
dose and the initiation of a CNB (manufacturers
recommendation).
3. Spinal anesthesia: when spinal anesthesia has been
performed, rivaroxaban can be given at 6 – 8 hours
after wound closure as thromboprophylaxis. If a
traumatic puncture occurs the first dose should be
delayed for 24 hours.
4. Epidural anesthesia: it is possible to perform epi-
dural anesthesia with a permanent catheter for post-
operative analgesia. The first dose with catheter in
place will be given 6–10 hours after the end of
surgery. Between the administration of drug and
the removal of catheter it is necessary at least 18
hours. In elderly patients, due to prolonged half-
-life this time shold be longer and it could be
established in 22– 26 hours. The minimal interval
between catheter removal and next dose of riva-
roxaban should be 4 hours.
Regional anesthesia was performed in more than half
of patients included in clinical trials but no information
regarding needle placement or catheter introduction was
included. Although there have been no reported spinal
hematomas, the lack of information regarding specifics
or regional anesthesia and the prolonged half life war-
rants a cautious approach (11,12).
Dabigatran
Direct thrombin inhibitors are new class of anticoagu-
lants used primarily in the treatment of heparin-induced
thrombocytopenia and percutaneous coronary interven-
tions. Dabigtran etexilate is prodrug that inhibits both
free and clot-bound thrombin. The drug is absorbed
from the gastrointestinal tract with bioavaliabity of 5%.
After absorbtion is converted to active metabolite, da-
bigatran. Plasma level peak at 2 hours. The half life is 8
hours after single dose and up to 17 hours after multiple
doses. Because 80% of the drug is excreted unchanged by
the kidneys, it is contraindicated in patients with renal
failure. Its elimination is dependent on kidney function,
and is contraindicated in patients with severe renal im-
pairment (creatine clearence < 30 ml/min). In patients
with creatine clereance 30 – 50 ml/min and in patients
over 75 years the daily dose should be reduced to 150 mg.
It is not recommended in patients with elevated liver
enzymesmore than two times the upper limit of normal.
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There is no specific antidote, but reversal of anticoa-
gulant effect is theoretically possible with administration
of recombinant factor VIIa, although this has not been
atempted clinically. In the case of bleeding the best op-
tion could be to administer prothrombin concentrates or
fresh frozen plasma depending on the modification of
clotting tests.
Dabigatran has been licensed for thromboprophylaxis
in patients undegoing hip or knee arthroplasty and is
under evaluation in ongoing trials for prevention of stroke
in patients with atrial fibrillation, acute VTE treatment
and secondary prevention of cardiac events in patients
with acute coronary syndrome.
There aremany clinical trials comparing thromboem-
bolic events in patients with joint replacement receiving
dabigatran or LMWH (enoxaparin). According these
studies the incidence of thromboembolic events is less
with administration of dabigatran. Dose recommenda-
tions are 110 mg 1 to 4 hours after surgery, and thereafter
220 mg/day for up to 35 days. The dosing is once daily
given perorally.
Anesthetic management of the patient
receiving Dabigatran
1. The first dose of dabigatran should be given no less
than 6 hours after a CNB or catheter removal.
2. The first dose should wait a minimum of 2 hours
after removal of an epidural catheter (manufactu-
rers recommendation).
3. Spinal anesthesia: after performing spinal atrau-
matic anesthesia the first dose can be given at 1–4
hours after the end of surgery. If a traumatic/he-
morrhagic puncture occurs the first dose of dabiga-
tran should be delayed for 24 hours.
4. Epidural aneshesia: dabigatran cannot be admini-
stered if epidural anesthesia with insertion of per-
manent catheter has been performed. Once a dose
of the anticoagulant has been given, the safety time
between the removal of catheter and the next admi-
nistration of drug would be 36 hours, but this
practice has not been valid anywhere.
Among published studies there was no randomisation
regarding anesthetic technique or criteria based on the
performance of neuraxial block, including the presence
of an indwelling catheter or traumatic needle/catheter
placement. There have been no reported spinal hema-
tomas, but the lack of information regarding the specifcs
of block performance and the prolonged half-life war-
rants cautious approach (11,12).
Is important to notice that first dose of new anticoagu-
lants is given postoperatively, so neuraxial blockade per-
formed preoperatively is safe procedure. The question is
safety of neuraxial blockade in patients receiving new
anticoagulants for thromboprophylaxis who needed re-
operation. The number of these patients is small, and
there is no reported study of these problem. There is also
no case report of possible complication in these patients
so further investigation is needed.
Antiplatelet medications
There are two types of antiplatelet agents: agents with
irreversibly and agents with reversibly inhibition of pla-
telet function. Antiplatelet agents that irreversibly inhibit
platelet function include ASA, clopidogrel, ticlopidin and
prasurgel. For each day after interruption of any ot these
agents 10% to 14% of normal platelet function is restored,
so it takes 7 to 10 days for an entire platelet pool to be
replenished.
Antiplatelet drugs that reversibly inhibit platelet func-
tion include dipyridamole and nonsteroidal antiinflam-
matory drugs. Dipyridamole has a half-life of 10 h, non-
steroidal antiinflammatory drugs have half-lives that vary
from 2 to 6 h (ibuprofen, ketoprofen, indometacin), to 7
to 15 h (celecoxib, naproxen) to > 20 h (piroxicam).
In order to restore platelet function and to avoid bleed-
ing the recommendation is preoperative stopping of anti-
platelet medication. But according recent CHEST re-
commendations in patients at moderate to high risk for
cardiovascular events who are receiving ASA therapy and
require noncardiac surgery continuing ASA around the
time of surgery instead of stopping ASA 7 to 10 days
before surgery is recommended. In patients at low risk
stopping of ASA is suggested.
Special caution is given to patients with coronary
stents having surgery. The number of these patients is
growing, so one retrospective study of 17.797 stented
patients found that 11% of patients require surgery dur-
ing a 2 year period after stent placement and that 4%
required surgery within 1 year of stent placement (13).
Patientmanagement is problematic because of concerns
about the incidence of stent related coronary thrombosis
if antiplatelet therapy is interrupted. In several retro-
spective studies with > 2.200 patients who had surgery
within 2 years of stent placement the incidence of post-
operative stent thrombosis was 2% and 5% (14).
The possible role of the bridging therapy in patients
with coronary stents who require surgery is uncertain.
There are only a few case reports assesed the use of short
acting antiplatelet drugs such as UFH, LMWHs or gly-
coprotein IIb/IIIa antagonists in the perioperative setting.
Studies are needed to asses the role of bridging therapy (7).
Recent recommendations suggest that in patients with
a coronary stent who receiving dual antiplatelet therapy
the surgery should be postponed for at least 6 weeks after
placement of a bare-metal stent and for a least 6 months
after placement a drug-eluciting stent. In patients who
require surgery in this period continuing dual therapy
around the time of surgery is recommended instead of
stopping antiplatelet therapy 7 to 10 days before surgery.
The question is how to perform regional anesthesia in
patients with stents. Is neuraxial blockade contraindicated
in this period? Several large studies demonstrated safety of
central blockade in patients receiving ASA or NSAID
preoperatively. There is no large studies with patients
receiving ticlopidin or clopidogrel, but there are case
Period biol, Vol 115, No 2, 2013. 129
Controversies in regional anaesthesia - patient on anticoagulant therapy B. Tripkovi}
reports of 3 spinal hematomas attributed to neuraxial
technique and ticlopidine or clopidogrel (7, 15).
Anesthetic management of the patient receiving anti-
platelet medication1.
1. Nonsteroidal anti-inflammatory drugs seem to re-
present no added significant risk for spinal hema-
toma in patients having spinal/epidural anesthesia.
2. The actual risk of spinal hematomawith ticlopidin
and clopidogrel is unknown. The normalization of
platelet function is needed before spinal/epidural
anesthesia, so discontinuation of therapy is recom-
mended. The suggested time interval between dis-
continuation and neuraxial anesthesia is 14 days
for ticlopidine and 7 days for clopidogrel.
3. In patients with coronary stent who needed conti-
nuing therapy around the time of surgery the neu-
raxial anesthesia is not recommended.
CONCLUSION
The alarmingly high incidence od spinal hematomas
reported during 1990s after introduction of LMWH for
thromboprophylaxis led to numerous national and inter-
national guidelines intented to reduce the risk of spinal
bleeding were CNBs are performed in patients given
anticoagulated drugs. The new anticoagulated drugs in-
troduced in last 10 years (fondaparinux, rivaroxaban and
dabigatran) are administered with great caution in pa-
tients receiving spinal/epidural anesthesia. Special cau-
tion is also given to patients receiving antiplatelet medi-
cations. Pharmacologic properties are very important for
safe management of these drugs and CNBs. Elimination
half time, peak effect, time needed for cloth formation
must be calculated before performing spinal/epidural
anesthesia and catheter placement. With this cautious
approach the danger of spinal bleeding is minimum.
Unfortunatelly there are no prospective randomised stu-
dies analysing regional anesthesia and new anticoagulat-
ed drugs or antiplatelet medications in patients with
coronary stent, and further investigations are necessary
before definitive recommendations of performing spi-
nal/epidural anesthesia and catheter manipulation will
be proposed.
Reported studies confirmed safe use of regional anesthe-
sia procedures in patients taken anticoagulated drugs. It
should be remmembred that decision to perform regio-
nal anesthesia in the patients receiving antithrombotic
drugs should be made on an individual basis weighing
risk of neuraxial bleeding with the benefits of regional
anesthesia. The procedures of regional anesthesia must
be performed according the guidelines of blockade in
anticoagulated patients.
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